New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
Abstract
:1. Introduction
2. Neurobiology of Schizophrenia
2.1. Dysregulation of the Dopaminergic System
2.2. Glutamatergic Transmission Disorder
2.3. Increased Serotonergic Transmission in the Cortex
3. Neurobiology of Depression
3.1. The Monoaminergic Hypothesis
3.2. Neurogenesis and Neuroplasticity
4. New Atypical Antipsychotics in the Treatment of Schizophrenia
5. New Atypical Antipsychotics in the Treatment of Depression
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Delay, J.; Deniker, P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J. Clin. Exp. Psychopathol. 1955, 16, 104–111. [Google Scholar] [PubMed]
- Grinchii, D.; Dremencov, E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int. J. Mol. Sci. 2020, 21, 9532. [Google Scholar] [CrossRef] [PubMed]
- Grace, A.A.; Gomes, F.V. The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention. Schizophr Bull. 2019, 45, 148–157. [Google Scholar] [CrossRef]
- Kahn, R.S.; Sommer, I.E.; Murray, R.M.; Meyer-Lindenberg, A.; Weinberger, D.R.; Cannon, T.D.; O’Donovan, M.; Correll, C.U.; Kane, J.M.; van Os, J.; et al. Schizophrenia. Nat. Rev. Dis. Primers 2015, 12, 15067. [Google Scholar] [CrossRef]
- Carbon, M.; Correll, C.U. Thinking and acting beyond the positive: The role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014, 19 (Suppl. S1), 38–52. [Google Scholar] [CrossRef] [PubMed]
- Dean, J.; Keshavan, M. The neurobiology of depression: An integrated view. Asian J. Psychiatr. 2017, 27, 101–111. [Google Scholar] [CrossRef]
- Grace, A.A. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat. Rev. Neurosci. 2016, 17, 524–532. [Google Scholar] [CrossRef]
- Howes, O.D.; McCutcheon, R.; Owen, M.J.; Murray, R.M. The role of genes, stress, and dopamine in the development of schizophrenia. Biol. Psychiatry 2017, 81, 9–20. [Google Scholar] [CrossRef]
- Stepnicki, P.; Kondej, M.; Kaczor, A.A. Current concepts and treatments of schizophrenia. Molecules 2018, 23, 2087. [Google Scholar] [CrossRef]
- Angrist, B.; Sathananthan, G.; Wilk, S.; Gershon, S. Amphetamine psychosis: Behavioral and biochemical aspects. J. Psychiatr. Res. 1974, 11, 13–23. [Google Scholar] [CrossRef]
- Tobias, J.A.Y.; Merlis, S. Levodopa and schizophrenia. JAMA 1970, 211, 1857. [Google Scholar] [CrossRef] [PubMed]
- Balu, D.T. The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. Adv. Pharmacol. 2016, 76, 351–382. [Google Scholar] [CrossRef] [PubMed]
- Stahl, S.M. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: Dopamine, serotonin, and glutamate. CNS Spectr. 2018, 23, 187–191. [Google Scholar] [CrossRef]
- Kahn, R.S.; Sommer, I.E. The neurobiology and treatment of first-episode schizophrenia. Mol. Psychiatry 2015, 20, 84–97. [Google Scholar] [CrossRef]
- Geyer, M.A.; Vollenweider, F.X. Serotonin research: Contributions to understanding psychoses. Trends Pharmacol. Sci. 2008, 29, 445–453. [Google Scholar] [CrossRef]
- Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27, 1159–1172. [Google Scholar] [CrossRef] [PubMed]
- Lizarraga, K.J.; Fox, S.H.; Strafella, A.P.; Lang, A.E. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin. Geriatr. Med. 2020, 36, 105–118. [Google Scholar] [CrossRef] [PubMed]
- Pahwa, M.; Sleem, A.; Elsayed, O.H.; Good, M.E.; El-Mallakh, R.S. New antipsychotic medications in the last decade. Curr. Psychiatry Rep. 2021, 29, 87. [Google Scholar] [CrossRef]
- Hamon, M.; Blier, P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 1, 54–63. [Google Scholar] [CrossRef]
- De Deurwaerdère, P.; Di Giovanni, G. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. Prog. Neurobiol. 2017, 151, 175–236. [Google Scholar] [CrossRef]
- Ceskova E and Silhan, P. Novel treatment options in depression and psychosis. Neuropsychiatr. Dis. Treat. 2018, 14, 741–747. [Google Scholar] [CrossRef]
- Slifirski, G.; Król, M.; Turło, J. 5-HT Receptors and the development of new antidepressants. Int. J. Mol. Sci. 2021, 22, 9015. [Google Scholar] [CrossRef] [PubMed]
- Taliaz, D.; Stall, N.; Dar, D.E.; Zangen, A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol. Psychiatry 2010, 15, 80–92. [Google Scholar] [CrossRef] [PubMed]
- Krishnan, V.; Nestler, E. The molecular neurobiology of depression. Nature 2008, 455, 894–902. [Google Scholar] [CrossRef] [PubMed]
- Hall, J.; Thomas, K.L.; Everitt, B.J. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. Nat. Neurosci. 2000, 3, 533–535. [Google Scholar] [CrossRef]
- Li, P.; Snyder, G.L.; Vanover, K.E. Dopamine targeting drugs for the treatment of schizophrenia: Past, present and future. Curr. Top. Med. Chem. 2016, 16, 3385–3403. [Google Scholar] [CrossRef]
- Martinowich K and Lu, B. Interaction between BDNF and serotonin: Role in mood disorders. Neuropsychopharmacology 2008, 33, 73–83. [Google Scholar] [CrossRef]
- Szapacs, M.E.; Mathews, T.A.; Tessarollo, L.; Ernest, L.W.; Mamounas, L.A.; Andrews, A.M. Exploring the relationship between serotonin and brain-derived neurotrophic factor: Analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J. Neurosci. Methods 2004, 140, 81–92. [Google Scholar] [CrossRef]
- Pourhamzeh, M.; Moravej, F.G.; Arabi, M.; Shahriari, E.; Mehrabi, S.; Ward, R.; Ahadi, R.; Joghataei, M.T. The roles of serotonin in neuropsychiatric disorders. Cell Mol. Neurobiol. 2022, 42, 1671–1692. [Google Scholar] [CrossRef]
- Selvaraj, S.; Arnone, D.; Cappai, A.; Howes, O. Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci. Biobehav. Rev. 2014, 45, 233–245. [Google Scholar] [CrossRef]
- Kikuchi, T.; Maeda, K.; Suzuki, M.; Hirose, T.; Futamura, T.; McQuade, R.D. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacol. Rep. 2021, 41, 134–143. [Google Scholar] [CrossRef] [PubMed]
- Hope, J.; Keks, N.A. Cariprazine: A new partial dopamine agonist with a familiar profile. Australas Psychiatry 2022, 30, 382–385. [Google Scholar] [CrossRef] [PubMed]
- Hsu, W.Y.; Lane, H.Y.; Lin, C.H. Brexpiprazole for the treatment of schizophrenia. Expert. Opin. Pharmacother. 2017, 18, 217–223. [Google Scholar] [CrossRef] [PubMed]
- Frampton, J.E. Brexpiprazole: A Review in Schizophrenia. Drugs 2019, 79, 189–200. [Google Scholar] [CrossRef] [PubMed]
- Marder, S.R.; Hakala, M.J.; Josiassen, M.K.; Zhang, P.; Ouyang, J.; Weiller, E.; Weiss, C.; Hobart, M. Brexpiprazole in patients with schizophrenia: Overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017, 29, 278–290. [Google Scholar] [CrossRef]
- Watanabe, Y.; Yamada, S.; Otsubo, T.; Kikuchi, T. Brexpiprazole for the treatment of schizophrenia in adults: An overview of its clinical efficacy and safety and a psychiatrist’s perspective. Drug Des. Devel. Ther. 2020, 14, 5559–5574. [Google Scholar] [CrossRef]
- Ishigooka, J.; Iwashita, S.; Tadori, Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin. Neurosci. 2018, 72, 692–700. [Google Scholar] [CrossRef]
- Newcomer, J.W.; Eriksson, H.; Zhang, P.; Weiller, E.; Weiss, C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: Pooled analyses of phase 3 clinical studies. Curr. Med. Res. Opin. 2018, 34, 2197–2205. [Google Scholar] [CrossRef]
- Calabrese, F.; Tarazi, F.I.; Racagni, G.; Riva, M.A. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020, 25, 343–351. [Google Scholar] [CrossRef]
- Jaeschke, R.R.; Sowa-Kućma, M.; Pańczyszyn-Trzewik, P.; Misztak, P.; Styczeń, K.; Datka, W. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacol. Rep. 2016, 68, 748–755. [Google Scholar] [CrossRef]
- Risbood, V.; Lee, J.R.; Roche-Desilets, J.; Fuller, M.A. Lurasidone: An atypical antipsychotic for schizophrenia. Ann. Pharmacother. 2012, 46, 1033–1046. [Google Scholar] [CrossRef] [PubMed]
- Zheng, W.; Cai, D.B.; Yang, X.H.; Li, L.; Zhang, Q.E.; Ng, C.H.; Ungvari, G.S.; Li, X.B.; Ning, Y.P.; Xiang, Y.T. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. J. Psychiatr. Res. 2018, 103, 244–251. [Google Scholar] [CrossRef] [PubMed]
- Bruijnzeel, D.; Yazdanpanah, M.; Suryadevara, U.; Tandon, R. Lurasidone in the treatment of schizophrenia: A critical evaluation. Expert Opin. Pharmacother. 2015, 16, 1559–1565. [Google Scholar] [CrossRef] [PubMed]
- Ceskova, E. Pharmacological strategies for the management of comorbid depression and schizophrenia. Expert. Opin. Pharmacother. 2020, 21, 459–465. [Google Scholar] [CrossRef]
- Musselman, M.; Faden, J.; Citrome, L. Asenapine: An atypical antipsychotic with atypical formulations. Ther. Adv. Psychopharmacol. 2021, 11. [Google Scholar] [CrossRef]
- Matsuzaki, H.; Hatano, M.; Iwata, M.; Yamada, S. Treatment continuation of asenapine or olanzapine in Japanese schizophrenia patients: A Propensity Score Matched Study. Neuropsychiatr. Dis. Treat. 2021, 17, 3655–3661. [Google Scholar] [CrossRef]
- Plosker, G.L.; Deeks, E.D. Asenapine: A Review in Schizophrenia. CNS Drugs 2016, 30, 655–666. [Google Scholar] [CrossRef]
- Suzuki, K.; Castelli, M.; Komaroff, M.; Starling, B.; Terahara, T.; Citrome, L. Pharmacokinetic profile of the asenapine transdermal System (HP-3070). J. Clin. Psychopharmacol. 2021, 41, 286–294. [Google Scholar] [CrossRef]
- Landbloom, R.; Mackle, M.; Wu, X.; Kelly, L.; Snow-Adami, L.; McIntyre, R.S.; Mathews, M.; Hundt, C. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr. 2017, 22, 333–341. [Google Scholar] [CrossRef]
- Dogterom, P.; Riesenberg, R.; de Greef, R.; Dennie, J.; Johnson, M.; Pilla Reddy, V.; Miltenburg, A.M.; Findling, R.L.; Jakate, A.; Carrothers, T.J.; et al. Asenapine pharmacokinetics and tolerability in a pediatric population. Drug. Des. Devel. Ther. 2018, 12, 2677–2693. [Google Scholar] [CrossRef] [Green Version]
- Meltzer, H.Y.; Mills, R.; Revell, S.; Williams, H.; Johnson, A.; Bahr, D.; Friedman, J.H. Pimavanserin, a serotonin(2A) receptor inverse agonists, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 2010, 35, 881–892. [Google Scholar] [CrossRef] [PubMed]
- Hacksell, U.; Burstein, E.S.; McFarland, K.; Mills, R.G.; Williams, H. On the discovery and development of pimavanserin: A novel drug candidate for Parkinson’s Disease psychosis. Neurochem. Res. 2014, 39, 2008–2017. [Google Scholar] [CrossRef] [PubMed]
- Nasrallah, H.A.; Fedora, R.; Morton, R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Schizophr. Res. 2019, 208, 217–220. [Google Scholar] [CrossRef]
- Samochowiec, J.; Dudek, D.; Kucharska-Mazur, J.; Murawiec, S.; Rymaszewska, J.; Cubała, W.J.; Heitzman, J.; Szulc, A.; Bała, M.; Gałecki, P. Pharmacological treatment of a depressive episode and recurrent depressive disorder–guidelines of the Polish Psychiatric Association and the National Consultant for Adult Psychiatry. Psychiatr. Pol. 2021, 55, 235–259, (English, Polish). [Google Scholar] [CrossRef] [PubMed]
- Kondo, T.; Shinzato, H.; Koda, M. Diagnostic and therapeutic considerations in depressive mixed state. Clin. Neuropsychopharmacol. Ther. 2016, 7, 41–47. [Google Scholar] [CrossRef]
- Zhou, X.; Keitner, G.I.; Qin, B.; Ravindran, A.V.; Bauer, M.; Del Giovane, C.; Zhao, J.; Liu, Y.; Fang, Y.; Zhang, Y.; et al. Atypical antipsychotic augmentation for treatment-resistant depression: A systematic review and network meta-analysis. Int. J. Neuropsychopharmacol. 2015, 18, pyv060. [Google Scholar] [CrossRef]
- Nelson, J.C.; Papakostas, G.I. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166, 980–991. [Google Scholar] [CrossRef]
- Gabriel, F.C.; de Melo, D.O.; Fráguas, R.; Leite-Santos, N.C.; Mantovani da Silva, R.A.; Ribeiro, E. Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. PLoS ONE 2020, 15, e0231700. [Google Scholar] [CrossRef]
- Spielmans, G.I.; Berman, M.I.; Linardatos, E.; Rosenlicht, N.Z.; Perry, A.; Tsai, A.C. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013, 10. [Google Scholar] [CrossRef]
- Rybakowski, J. Etiopathogenesis of bipolar affective disorder—The state of the art for 2021. Psychiatr. Pol. 2021, 30, 481–496, (English, Polish). [Google Scholar] [CrossRef]
- Lenze, E.J.; Mulsant, B.H.; Blumberger, D.M.; Karp, J.F.; Newcomer, J.W.; Anderson, S.J.; Dew, M.A.; Butters, M.A.; Stack, J.A.; Begley, A.E.; et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: A randomised, double-blind, placebo-controlled trial. Lancet 2015, 386, 2404–2412. [Google Scholar] [CrossRef]
- Haupt, D.W.; Fahnestock, P.A.; Flavin, K.A.; Schweiger, J.A.; Stevens, A.; Hessler, M.J.; Maeda, J.; Yingling, M.; Newcomer, J.W. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007, 32, 2561–2569. [Google Scholar] [CrossRef] [PubMed]
- Keramatian, K.; Chakrabarty, T.; Saraf, G.; Yatham, L.N. New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: A Systematic Review of Recent Randomized Controlled Trials. Curr. Psychiatry Rep. 2021, 23, 39. [Google Scholar] [CrossRef] [PubMed]
- Loebel, A.; Cucchiaro, J.; Silva, R.; Kroger, H.; Hsu, J.; Sarma, K.; Sachs, G. Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171, 160–168. [Google Scholar] [CrossRef]
- Loebel, A.; Cucchiaro, J.; Silva, R.; Kroger, H.; Sarma, K.; Xu, J.; Calabrese, J.R. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171, 169–177. [Google Scholar] [CrossRef]
- El-Mallakh, R.S.; Nuss, S.; Gao, D.; Gao, Y.; Ahmad, S.C.; Schrodt, C.; Adler, C. Asenapine in the Treatment of Bipolar Depression. Psychopharmacol. Bull. 2020, 50, 8–18. [Google Scholar]
- Szegedi, A.; Zhao, J.; van Willigenburg, A.; Nations, K.R.; Mackle, M.; Panagides, J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011, 11, 101. [Google Scholar] [CrossRef]
- Soogrim, V.; Ruberto, V.L.; Murrough, J.; Jha, M.K. Spotlight on pimavanserin tartrate and its therapeutic potential in the treatment of major depressive disorder: The evidence to date. Drug Des. Devel. Ther. 2021, 15, 151–157. [Google Scholar] [CrossRef]
- Jha, M.K.; Fava, M.; Freeman, M.P.; Thase, M.E.; Papakostas, G.I.; Shelton, R.C.; Trivedi, M.H.; Dirks, B.; Liu, K.; Stankovic, S. Effect of adjunctive pimavanserin on sleep/wakefulness in patients with major depressive disorder: Secondary analysis from CLARITY. J. Clin. Psychiatry 2020, 82, 20m13425. [Google Scholar] [CrossRef]
Name od Drug | Aripiprazole | Brexpiprazole | Cariprazine | Lurasidone | Asenapine | Lumateperone | Pimavanserin |
---|---|---|---|---|---|---|---|
Mechanism of action | D2 partial agonist 5-HT1A partial agonist 5-HT2A antagonist | D2/D3 partial agonist 5-HT1A partial agonist 5-HT2A antagonist α1B/2C antagonist low affinity for H1 and M1 receptors | D2/D3 partial agonist 5-HT1A partial agonist low affinity for H1 and 5-HT2A receptors lack of affinity for M receptors | D2, 5-HT2A and 5-HT7 antagonist 5-HT1A partial agonist an affinity for adrenergic receptors–higher for α2C and slightly lower for α1 and α2A very low affinity for D1, 5-HT2C, H1 and M1 receptors | D2, 5-HT2A, 5-HT2C and 5-HT7 antagonist an affinity for adrenergic receptors –α1 and α2 lack of affinity for M receptors | full postsynaptic D2 antagonist D2 partial presynaptic agonist 5-HT2A antagonist D1 agonist SERT inhibitor | 5-HT2A and 5-HT2C inverse agonist lack of affinity for DA receptors |
Indications | schizophrenia acute mania unipolar depression (adjunct) | schizophrenia unipolar depression (adjunct) | schizophrenia acute mania | schizophrenia depressive symptoms in BD (monotherapy and adjunct) | schizophrenia BD (acute mixed and manic episodes) | schizophrenia | Parkinson’s disease psychosis |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Orzelska-Górka, J.; Mikulska, J.; Wiszniewska, A.; Biała, G. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. Int. J. Mol. Sci. 2022, 23, 10624. https://doi.org/10.3390/ijms231810624
Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International Journal of Molecular Sciences. 2022; 23(18):10624. https://doi.org/10.3390/ijms231810624
Chicago/Turabian StyleOrzelska-Górka, Jolanta, Joanna Mikulska, Anna Wiszniewska, and Grażyna Biała. 2022. "New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression" International Journal of Molecular Sciences 23, no. 18: 10624. https://doi.org/10.3390/ijms231810624